AstraZeneca: discovering a possible new side effect of the vaccine

After the strange cases of thrombosis detected in very few people who had been vaccinated with AstraZeneca, the safety committee of the European Medicines Agency (EMA) warned of a possible new opposite effect vaccine: systemic capillary leak syndrome (CLS).

As stated, this is a blood disease severe and very rare, characterized by an increase in permeability capillary which allows the escape fluids and proteins from the circulatory system to the interstitial space, which can lead to a shock Yes massive edema.

// Today a shipment arrives with 934,200 vaccines from AstraZeneca and Argentina will exceed 20 million doses: to which laboratory each corresponds

For this reason, they warned, people who have suffered from the disease at some point in their lives should not be vaccinated with the AstraZenecabecause liquids escape from the blood vessels smaller and cause swelling and drop in blood pressure.

In April of this year, the EMA began investigating this possible new side effect vaccine. After the detection of rare – and even fatal – cases of blood clotting with a low platelet count, they warned against the use of this drug. The committee reviewed six validated cases of CLS in people, primarily women, who had received Vaxzevria, including one death. Three are said to have had a history of the disease.

// Novavax Says Its Coronavirus Vaccine Is 90% Effective: What Are Its Benefits

In the European Union, over 78 million dose of AstraZeneca, the laboratory of which published a statement in which it noted the extreme rarity of CLS cases: less than 1 in 10 million of people vaccinated.

The company said: “We are actively working, in collaboration with regulatory authorities, on measures to risk minimization which includes information for those vaccinated, information to promote early diagnosis and intervention and appropriate treatment ”.

For its part, Medicines and Health Products Regulatory Agency (MHRA) – the British regulator – assured that he was considering precautionary advice for people with CLS Context, but they clarified that they do not see a direct link to the vaccine. Two of the eight reports capillary leak syndrome after the AstraZeneca vaccination in the UK they were in people with a history of the disease and had been administered 40 million doses vaccine, the MHRA said.

// Despite having vaccinated more than 50% of their population, UK and Chile are sounding global alarm bells ahead of surge in coronavirus infections

Meanwhile, the EMA continues to investigate cases of inflammation cardiac (myocarditis) in people who have been vaccinated against the coronavirus with the different brands of vaccines currently on the market. However, several EU Member States have restricted the use of Astrazeneca to those who have entered 50 and 65 for unusual cases of blood clots

US authorities have reported that they have recorded a higher than expected number of cases of heart inflammation in young men who received a second dose of injections of MRNA, although a causal relationship with vaccines could not be established. However, from Israel they recognized that those who had suffered heart inflammation had been inoculated with Pfizer / BioNTech.

For its part, BioNTech indicated that the myocarditis and the pericarditis detected in some patients are subject to regular and exhaustive review by companies and regulatory authorities. “More … than 300 million doses Pfizer-BioNTech COVID-19 vaccine and the profile of risk-benefit of our vaccine is still positive, ”they maintained.